1. Summary of the Week
From July 18 to 24, a total of 24 agreements were signed worldwide. Within China’s biotech industry, there was one in-licensing deal, one out-licensing deal, and four domestic transactions.
In China, the largest deal involved TYK Medicines and Qilu Pharmaceutical for the filed asset asandeutertinib, with an upfront payment of $42 million and a total deal value of $384 million.
Globally, 18 deals were announced. The largest deal involved Royalty Pharma and Neurimmune for AstraZeneca’s Phase III asset cliramitug, with an upfront payment of $125 million and a total deal value of up to $425 million.
2026年7月18日-24日，全球医药市场共签署了24项资产授权和合作协议。中国市场共达成6项交易，包括1项引进交易、1项出海交易和4项国内交易。
国内市场上，本周最大的国内交易是同源康医药与齐鲁制药就已申报上市资产asandeutertinib达成在中国大陆区域的许可与合作及供应和商业化协议，首付款4200万美元，总金额可达3.84亿美元。
国际市场上，本周共签署了18项资产授权和合作协议。最大的交易是Royalty Pharma从Neurimmune手中收购阿斯利康临床三期资产cliramidut的部分特许权权益，首付款1.25亿美元，总金额可达4.25亿美元。
2. Licensing Deals
China Licensing and Cooperation Deals July 2026
| Deal Type | Licensor | Licensee | Assets | Disease | Stage | Total amount ($ million) |
Upfront ($ million) |
Deal Territory |
|---|---|---|---|---|---|---|---|---|
| China IL | Tempest Therapeutics | Senlang Biotechnology 森朗生物 |
TPST-4003 | multiple sclerosis (MS); myasthenia gravis (MG); oncology; autoimmune disease | Pre-Clinical | Undisclosed | Undisclosed | Chinese Mainland |
| China OL | CanSino 康希诺 |
AGP | PCV13 | bacterial pneumonia; meningitis; pneumonitis; epidemic cerebrospinal meningitis; multiple sclerosis (MS); HIV-1 infection; sepsis; S. pneumoniae infection; bacteremia | Approved | Undisclosed | Undisclosed | Other |
| China Domestic | TYK Medicines 同源康医药 |
Qilu Pharmaceutical 齐鲁制药 |
asandeutertinib | non-small cell lung cancer (NSCLC); brain metastasis; leptomeningeal carcinomatosis | Filed | 384 | 42 | Chinese Mainland |
| China Domestic | Byterna 元码智药 |
Insilico Medicine; duneQ 英矽智能; 沙丘量子 |
Circular mRNA “Quantum + AI” Technology Platform | Undisclosed | Undisclosed | Undisclosed | Undisclosed | Global |
| China Domestic | SunNovo 阳光诺和 |
Gem Pharma 药康生物 |
AOC program; pharmacological effect model | rare disease; aging; disorder of nervous system; metabolic disease; autoimmune disease | Pre-Clinical | Undisclosed | Undisclosed | Global |
| China Domestic | Eli Radiopharma 亦立医药 |
Smart Logic 思朗科技 |
Cyclic Peptide Molecular Resource Platform; Radiopharmaceutical Research and Development Project | oncology; neurology | Pre-Clinical | Undisclosed | Undisclosed | Global |
2a. China Section
3. Top Deals of 2026
Top China Out-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-01-30 | CSPC Pharma 石药集团 |
AstraZeneca | Endocrine & Metabolic | IND; Pre-Clinical | 18,500 | 1,200 |
| 2026-05-29 | Innovent Biologics 信达生物 |
Pfizer | Oncology | Pre-Clinical | 10,500 | 650 |
| 2026-01-13 | RemeGen 荣昌生物 |
AbbVie | Rare Disease; Oncology | Phase II | 5,600 | 650 |
| 2026-05-12 | Hengrui Pharmaceuticals 恒瑞医药 |
Bristol-Myers Squibb | Haematology; Oncology | Pre-Clinical | 15,200 | 600 |
| 2026-07-14 | Dizal Pharma 迪哲医药 |
AstraZeneca | Haematology; Oncology; Rare Diseases | Approved | 1,500 | 600 |
| 2026-02-08 | Innovent Biologics 信达生物 |
Eli Lilly | Immunology; Oncology | Pre-Clinical | 8,850 | 350 |
| 2026-07-08 | Chia Tai Tianqing Pharmaceutical 正大天晴 |
AstraZeneca | Respiratory | Phase III | 2,100 | 200 |
| 2026-02-02 | Sanegene Bio 圣因生物 |
Genentech Roche | Unknown/To be determined | Pre-Clinical | 1,700 | 200 |
| 2026-01-12 | SciNeuro Pharma 赛神医药 |
Novartis | Neurology | Pre-Clinical | 1,665 | 165 |
| 2026-03-04 | CTTQ Pharma 正大天晴 |
Sanofi | Hematology; Rare Disease; Immunology; Oncology | Approved | 1,530 | 135 |
Top China In-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-05-14 | AriBio | Fosun Pharmaceutical 复星医药 |
Neurology; Cardiovascular; Genitourinary | Approved | Undisclosed | 80 |
| 2026-04-17 | Aligos Therapeutics | Amoytop Biotech 特宝生物 |
Infection; Gastroenterology | Phase II | 445 | 25 |
| 2026-03-09 | Rapport Therapeutics | Tenacia Biotechnology 元羿生物 |
Neurology; Psychiatry | Phase II | 328 | 20 |
| 2026-07-03 | Adneuris Therapeutics | Conba Pharmaceutical 康恩贝 |
Anesthesiology; Musculoskeletal; Psychiatry; Oncology | Phase III | 111.5 | 17.5 |
| 2026-06-16 | Dimerix | Everest Medicines 云顶新耀 |
Infection; Genitourinary | Phase III | 340 | 10 |
Top China Domestic Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-07-21 | TYK Medicines 同源康医药 |
Qilu Pharmaceutical 齐鲁制药 |
Oncology | Filed | 384 | 42 |
| 2026-05-29 | Genrix Bio 智翔金泰 |
YaoPharma 药友制药 |
Hematology; Rare Diseases; Immunology; Dermatology; Oncology | Filed | 253 | 42 |
| 2026-03-23 | Corxel Pharmaceuticals 箕星药业 |
Everest Medicines 云顶新耀 |
Cardiovascular | Approved | 50 | 30 |
| 2026-02-05 | Micot Technology 麦科奥特 |
Everest Medicines 云顶新耀 |
Genitourinary; Endocrine & Metabolic | Phase III | 172.48 | 27.82 |
| 2026-01-17 | Raynovent 众生药业 |
Qilu Pharmaceutical 齐鲁制药 |
Gastroenterology; Respiratory; Endocrine & Metabolic | Phase III | 139.10 | 27.82 |
| 2026-04-28 | Huahui Health 华辉安健 |
BeOne Medicines 百济神州 |
Oncology | Pre-Clinical | 2,024 | 20 |
| 2026-01-12 | Wan Bang De 万邦德 |
Hisoar Pharmaceutical 海翔药业 |
Neurology; Rare Disease | Pre-Clinical | 20.87 | 16.69 |
| 2026-01-06 | Accendatech 尚德药缘 |
Yifan Pharmaceutical 亿帆医药 |
Neurology; Ophthalmology; Respiratory; Hematology; Rare Disease; Immunology; Oncology | Phase III | 20.87 | 13.91 |
| 2026-02-04 | Akeso Biopharma; Kangrong Dongfang 康方生物 |
Jumpcan Pharmaceutical 济川药业 |
Rare Disease; Cardiovascular | Approved | 12.52 | 11.13 |
| 2026-01-20 | Insilico Medicine 英矽智能 |
Hengtai Biotechnology 衡泰生物 |
Neurology | Pre-Clinical | 66 | 10 |
Top Global Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-03-20 | Synnovation Therapeutics | Novartis | Oncology | Phase I/II | 3,000 | 2,000 |
| 2026-06-01 | Edgewise Therapeutics | Servier | Musculoskeletal; Rare Diseases | Phase II | 2,650 | 1,550 |
| 2026-06-08 | Nurix Therapeutics | Roche | Haematology; Rare Diseases; Immunology; Oncology | Phase III | 2,300 | 700 |
| 2026-03-19 | Corium Therapeutics | Collegium Pharmaceutical | Psychiatry | Approved | 785 | 650 |
| 2026-03-09 | GSK | Alfasigma | Gastroenterology; Rare Disease; Dermatology; Endocrine & Metabolic | Filed | 690 | 300 |
| 2026-02-23 | Vir Biotechnology | Astellas Pharma | Oncology | Phase I/II | 1,705 | 240 |
| 2026-03-23 | Kali Therapeutics | Sanofi | Musculoskeletal; Immunology | Phase I | 1,230 | 180 |
| 2026-07-22 | Neurimmune; AstraZeneca | Royalty Pharma | Cardiovascular disease; Rare disease | Phase III | 425 | 125 |
| 2026-05-19 | Hansa Biopharma | Serb SA | Neurology; Rare Diseases; Musculoskeletal; Hematology; Immunology; Endocrinology & Metabolism | Approved | 130 | 124 |
| 2026-06-24 | Antares Therapeutics | Novartis | Oncology | Undisclosed | 1,905 | 105 |
4. 2021-2025 China Innovative Drug Licensing Transactions
BioToChina.org 